Abstract
The severity of disease following infection with SARS-CoV-2 is determined by viral replication kinetics and host immunity, with early T cell responses and/or suppression of viraemia driving a favourable outcome. Recent studies uncovered a role for cholesterol metabolism in the SARS-CoV-2 life cycle and in T cell function. Here we show that blockade of the enzyme Acyl-CoA:cholesterol acyltransferase (ACAT) with Avasimibe inhibits SARS-CoV-2 pseudoparticle infection and disrupts the association of ACE2 and GM1 lipid rafts on the cell membrane, perturbing viral attachment. Imaging SARS-CoV-2 RNAs at the single cell level using a viral replicon model identifies the capacity of Avasimibe to limit the establishment of replication complexes required for RNA replication. Genetic studies to transiently silence or overexpress ACAT isoforms confirmed a role for ACAT in SARS-CoV-2 infection. Furthermore, Avasimibe boosts the expansion of functional SARS-CoV-2-specific T cells from the blood of patients sampled during the acute phase of infection. Thus, re-purposing of ACAT inhibitors provides a compelling therapeutic strategy for the treatment of COVID-19 to achieve both antiviral and immunomodulatory effects.
Trial registration: NCT04318314.
Funder
Wellcome Trust
Medical Research Council
Chinese Academy of Medical Sciences
Oxford Medical Science Division Internal Research Fund
Cancer Research UK
UK Coronavirus Immunology Consortium
Royal Free Hospital
U.S. Food and Drug Administration
Medical Research Foundation
UK Research and Innovation
Japan Agency for Medical Research and Development
NIHR Oxford Biomedical Research Centre
Publisher
Public Library of Science (PLoS)
Subject
Virology,Genetics,Molecular Biology,Immunology,Microbiology,Parasitology
Reference84 articles.
1. WHO. WHO Coronavirus (COVID-19) Dashboard 13.10.2022. [cited 13 Oct 2022]. Available: https://covid19.who.int
2. Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States.;S Gupta;Health Affairs.,2021
3. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness;A Sheikh;The Lancet,2021
4. NIH. COVID-19 Treatment Guidelines 13.10.2022. 13 Oct 2022. Available: https://www.covid19treatmentguidelines.nih.gov/
5. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity;CR Moderbacher;Cell,2020
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献